Compare Johnson & Johnson (JNJ) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Norfolk Southern Corporation — how do they compare? Johnson & Johnson trades at $261.35 (market cap $618.09B), while Norfolk Southern Corporation trades at $317.43 (market cap $71.20B). The key difference: Johnson & Johnson is far larger — about 8.7× Norfolk Southern Corporation's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Norfolk Southern Corporation for 33 Days on average.
| JNJ | NSC | |
|---|---|---|
Market Cap | $618.09B | $71.20B |
Volume | 6,050,983 | 555,248 |
Sector | Health | Industrials |
52-Week High | $278.43 | $352.98 |
52-Week Low | $186.00 | $278.19 |
Typical Hold Time | 129 Days | 33 Days |
Enterprise Value | $646.37B | $86.75B |
Dividend Yield | 2.09% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Norfolk Southern (NSC) trades at $317.14, up 1.26% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $361.86. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Strong profitability is evidenced by a 21.02% net income margin and 16.97% ROE, while news highlights significant institutional investment and progress on the proposed merger with Union Pacific.
The outlook is positive, supported by earnings momentum and potential merger benefits, but risks include integration challenges, fuel cost pressures noted in recent news, and a relatively high P/E ratio of 27.05. The stock offers a dividend yield and growth potential, contingent on successful execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
